Figure 4.

TMEM158 downregulation is associated with AR signaling activity in CRPC cancers. (A–F) Pearson correlation analysis was conducted between the expression levels of AR and TMEM158 genes using the RNA-seq data from previously published datasets, as indicated in the figures. (G–I) Spearman correlation analysis of TMEM158 expression with the AR activity score (G) and NEPC score (H), as well as the group comparison of TMEM158 expression between CRPC and NEPC tumors (I), were conducted using the RNA-seq dataset (24) obtained from 429 patients with metastatic castration-resistant prostate cancers (Student t-test, *p < 0.05). (J–K) TMEM158 expression cDNA microarray datasets were extracted from NCBI GDS2057 (J) (27) and GDS3358 (K) (28). Briefly, LNCaP cells were treated with dihydrotestosterone (DHT, 10 nM) or kept in androgen-depleted media for 3-week or 5-month. Total RNAs were extracted for gene expression analysis using the Affymetrix Human Genome U133 Plus 2.0 Array. The asterisk indicates a significant difference from the vehicle or control culture condition (Student t-test, *p < 0.05). (L) LNCaP cells were exponentially grown in culture media supplied with 10% FBS or in 2% charcoal-stripped FBS. Cells were also treated with anti-AR agents Enzalutamide (Enz, 10 μM) or Abiraterone (Abi, 10 μM) in 2% charcoal-stripped FBS for 24 h. Cellular proteins were used for the anti-TMEM158 immunoblot assay. Action blot served as a protein loading control.